Abstract
A class of optimal covariate-adjusted response adaptive procedures is developed for phase III clinical trials when the treatment response is a survival time and there is random censoring. The basic aim is to develop an allocation design by combining the ethical aspects with statistical precision in a reasonable way under the presence of covariate information. Considering minimisation of total hazards as the ethical requirement, the proposed procedure is assessed in terms of the assignment to the better treatment and the efficiency (i.e. power) to detect a small departure in treatment effectiveness. The applicability of the proposed methodology is also illustrated using a real data set.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
